An Act to amend and reenact §§ 38.2-3407.15:5 and 38.2-3418.10 of the Code of Virginia, relating to health insurance; cost-sharing payments for insulin and diabetes equipment and supplies; limit.
HB1214 amends Virginia health insurance law to lower the maximum out-of-pocket cost for covered prescription insulin drugs. Under the bill, carriers must cap a covered person’s cost-sharing payment at no more than $35 per 30-day supply, down from the prior $50 cap, and the limit applies in the aggregate even if more than one insulin drug is prescribed. The bill also prohibits provider contracts from requiring pharmacies, pharmacy benefits managers, or covered persons to charge or collect more than the statutory cap.
The bill also revises Virginia’s diabetes coverage statute to clarify and expand coverage for diabetes-related equipment, supplies, and education. Covered benefits include blood glucose meters and strips, urine-testing strips, syringes, continuous glucose monitors and supplies, insulin pump supplies, and in-person outpatient self-management training and medical nutrition therapy for several categories of diabetes when prescribed by an authorized health care professional. The bill states that these equipment and supply items are not to be treated as durable medical equipment.
HB1214 directly amends §§ 38.2-3407.15:5 and 38.2-3418.10 of the Code of Virginia, affecting health insurers, health maintenance organizations, carriers, pharmacy benefits managers, pharmacies, and covered individuals with diabetes. It lowers the statutory insulin cost-sharing ceiling and reinforces that contractual arrangements cannot circumvent that cap. It also preserves and clarifies mandated diabetes coverage for equipment, supplies, and training, which may affect plan design, claims processing, and consumer out-of-pocket costs across individual and group health plans in Virginia.
The bill appears generally favorable and consumer-protective, with the policy direction aimed at reducing the financial burden of diabetes care. Because there are no committee transcripts or recorded votes provided, there is no documented opposition or debate in the supplied materials. The enacted chapter status suggests the measure advanced successfully through the legislative process.
The main policy tension inherent in the bill is between lowering patient costs and the potential increased expense or administrative burden for insurers, pharmacy benefits managers, and pharmacies. The specific reduction of the insulin cost-sharing cap from $50 to $35 may be the most notable point of contention, along with the prohibition on contract terms that would otherwise shift higher charges to patients. The diabetes coverage provisions are comparatively broad and likely less controversial, but they still expand mandated benefits and could draw concern from carriers over premium and utilization impacts.